Klugman KP, Madhi S a, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med. 2003;349: 1341–8. pmid:14523142 doi: 10.1056/nejmoa035060
[2]
Goldblatt D, Southern J, Ashton L, Richmond P, Burbidge P, Tasevska J, et al. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J. 2006;25: 312–9. pmid:16567982 doi: 10.1097/01.inf.0000207483.60267.e7
[3]
Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. Viboud C, editor. PLoS Med. 2013;10: e1001517. doi: 10.1371/journal.pmed.1001517. pmid:24086113
[4]
Andrews NJ, Waight P, Burbidge P, Pearce E, Roalfe L, Zancolli M, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. Elsevier Ltd; 2014;14: 839–46. doi: 10.1016/S1473-3099(14)70822-9. pmid:25042756
[5]
Wroe PC, Lee GM, Finkelstein J a, Pelton SI, Hanage WP, Lipsitch M, et al. Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J. 2012;31: 249–54. doi: 10.1097/INF.0b013e31824214ac. pmid:22173142
[6]
Dagan R, Givon-Lavi N, Porat N, Greenberg D. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial. Vaccine. Elsevier Ltd; 2012;30: 5132–40. doi: 10.1016/j.vaccine.2012.05.059. pmid:22683519
[7]
Goldblatt D, Southern J, Ashton L, Andrews N, Woodgate S, Burbidge P, et al. Immunogenicity of a reduced schedule of pneumococcal conjugate vaccine in healthy infants and correlates of protection for serotype 6B in the United Kingdom. Pediatr Infect Dis J. 2010;29: 401–5. doi: 10.1097/INF.0b013e3181c67f04. pmid:20010312
[8]
Borrow R, Goldblatt D, Finn A, Southern J, Ashton L, Andrews N, et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom. Infect Immun. 2003;71: 5549–55. pmid:14500473 doi: 10.1128/iai.71.10.5549-5555.2003
[9]
Rozenbaum MH, van Hoek AJ, Fleming D, Trotter CL, Miller E, Edmunds WJ. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ. 2012;345: e6879. doi: 10.1136/bmj.e6879. pmid:23103369
[10]
Joint Committee on Vaccination and Immunisation. JCVI statement on the use of meningococcal C vaccines in the routine childhood immunisation programme [Internet]. 2012 [cited 31 Oct 2014].
[11]
Advisory Committee on Immunization Practices (ACIP). ACIP meeting information [Internet]. 2014 [cited 25 Jul 2014].
[12]
Fleming-Dutra KE, Conklin L, Loo JD, Knoll MD, Park DE, Kirk J, et al. Systematic Review of the Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Vaccine-type Nasopharyngeal Carriage. Pediatr Infect Dis J. 2014;33 Suppl 2: S152–60. doi: 10.1097/INF.0000000000000083. pmid:24336057
[13]
Millar E V, O’Brien KL, Bronsdon M a, Madore D, Hackell JG, Reid R, et al. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44: 1173–9. pmid:17407035 doi: 10.1086/513199
